During treatment, the response requires assessment to check for clearance of external anogenital warts or actinic keratoses and decreased size or resolution of superficial basal cell carcinoma. Additionally, application site reactions and local cutaneous adverse effects may occur, and patients should have ongoing monitoring for these developments, which may also be indicative of treatment response.